Navigation Links
Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
Date:12/28/2007

de there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. currently co-promote VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patient
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
2. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
3. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Life Sciences Leader Joins Millennium Board of Directors
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
10. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 05, 2015 Franz Inc ., the ... announced that its flagship product, AllegroGraph, has been named a ... Market Update report. AllegroGraph is a high performance ... industry standards. Graph databases are skyrocketing in popularity and have ... a recent DBMS ranking by DB-Engines. , “We ...
(Date:5/5/2015)... 5, 2015   Tocagen Inc. , a ... R. Parkinson , M.D., a venture partner at ... the board of directors of Tocagen. Dr. Parkinson ... oncology clinical development, including leading clinical activities at ... of the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® ...
(Date:5/5/2015)... 2015 The Alliance for Clinical Research ... operating in the public interest, and Texas-based for-profit ... Communications Company, have formed a strategic alliance to create ... education across the healthcare and clinical research endeavor. ... patients and the public to be clearly heard in ...
(Date:5/4/2015)... GliaCure, a privately-held biotechnology company focused ... and neuropsychiatric disorders based on glial targets, announced ... in a Phase 1b clinical trial of its ... a potential disease-modifying treatment. GliaCure,s innovative approach to ... both promotes the clearance of amyloid and stimulates ...
Breaking Biology Technology:Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2
... Sept. 13Researchers at Vanderbilt University have developed a new technique ... biological tissue at multiple points simultaneously, a method that could ... grow and change shape. UV lasers are a ... make incisions by vaporizing one point at a time in ...
... FORT WORTH, Texas, Sept. 13, 2011 Healthpoint Biotherapeutics ... Operating Officer, and Robert Bancroft, Executive Vice President, Strategic ... Company, its commercial products and its R&D pipeline at ... is scheduled for the opening day of the conference, ...
... 2011 Microban recently conducted in vitro ... growth on High Consistency Rubber (HCR) silicone, which ... catheters.  Urinary infections are a costly source of ... had limited success in reducing infection rates. The ...
Cached Biology Technology:Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference 2Microban Medical Silver Antimicrobial Technologies for HCR Silicone Achieve 5 Log Reductions in Bacteria Growth and Prevent Biofilm Formation 2
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... The brilliance of butterfly wings has inspired a ... in the fields of security, energy and the environment. ... have just signed a collaborative contract to develop new ... Over the next three years a team of physicists ...
... A chemical culprit responsible for the rapid, mysterious death ... found by collaborating scientists at Rutgers University and the ... may hold unexpected promise in cancer research. The ... in a virus that has been attacking and killing ...
... WEST LAFAYETTE, Ind. - Researchers at Purdue University have ... in spinal cord injuries using nano-spheres that could be ... The synthetic "copolymer micelles" are drug-delivery spheres about 60 ... the diameter of a red blood cell. Researchers ...
Cached Biology News:£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3
... LAS-3000 imaging system combines new CCD ... interface, providing significantly improved system sensitivity ... The system is especially dedicated to ... system for Western blotting applications.,Fuiji's LAS-3000 ...
... LAS-3000mini is a compact image analysis ... and the perfect standard system for ... provides significantly improved system sensitivity for ... standards validate that Fujis LAS-3000 is ...
... 50 assays. The TUNEL-based assay kit ... control cells for convenient detection of DNA ... The assay offers an one-step labeling of ... is a hallmark of apoptosis in mammalian ...
SDS-OutT Precipitation Reagent...
Biology Products: